(Q24244255)

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Corticosteroid-Mediated Immunoregulation in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Prognosis in primary biliary cirrhosis: model for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

"Negative trials" are positive!

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

A prospective trial of colchicine for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Osteoporosis in primary biliary cirrhosis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

D-penicillamine for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Prednisolone for primary biliary cirrhosis--good news, bad news

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

D-penicillamine treatment improves survival in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A prospective trial of D-penicillamine in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Trial of penicillamine in advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

Prescribing habits in primary biliary cirrhosis: a national survey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021

The biochemical changes induced by cortico-steroids in xanthomatous biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003778.PUB2

7 January 2021